Stockholders’ Equity (Details Narrative) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
Jul. 30, 2024 |
Feb. 07, 2024 |
Dec. 31, 2022 |
Sep. 30, 2022 |
Aug. 01, 2022 |
Apr. 30, 2022 |
Mar. 11, 2022 |
Feb. 08, 2022 |
Dec. 28, 2021 |
Aug. 12, 2016 |
Jun. 30, 2024 |
Aug. 31, 2022 |
Apr. 30, 2022 |
Sep. 30, 2024 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Aug. 13, 2024 |
Aug. 31, 2023 |
Jan. 31, 2023 |
Jan. 11, 2023 |
Apr. 29, 2022 |
Mar. 09, 2021 |
Dec. 31, 2018 |
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for conversion of convertible debt, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297,625
|
105
|
|
|
|
|
|
|
|
|
| Debt, principal |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 345,139
|
|
|
$ 331,800
|
|
$ 846,806
|
$ 1,925,700
|
|
|
|
|
|
|
|
|
|
|
|
| Accrued interest settled with common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16,340
|
|
|
|
|
|
|
|
|
| Loss on settlement of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
762,186
|
|
|
43,414
|
|
833,501
|
477,221
|
|
$ 477,221
|
$ 1,795,652
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
|
|
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
127,260
|
|
|
|
|
| Exercise price per share |
|
|
$ 111.04
|
|
$ 20.00
|
$ 8.00
|
|
|
$ 8.00
|
|
|
$ 16.00
|
$ 8.00
|
|
|
|
|
|
|
|
|
|
$ 111.04
|
$ 8.00
|
|
|
$ 1.93
|
|
$ 16.00
|
|
|
| Aggregate intrinsic value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares vested under plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
60,048
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
227,886
|
95,438
|
|
181,960
|
$ 237,547
|
|
|
|
|
|
|
|
|
| Sale of stock consideration received per transaction |
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation arrangement by share based payment award description |
|
(i) one share of the Company’s
common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per
share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will
own a 22% interest in Diagnostics.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of common stock |
|
$ 4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Direct cost |
|
|
|
|
|
|
|
|
|
|
$ 142,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 101,651
|
|
|
|
|
$ 101,651
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock vesting of restricted stock unit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500
|
|
|
|
|
|
|
|
|
| Number shares issued for conversion of note, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,113
|
|
|
|
|
|
|
|
|
| Number shares issued for conversion dividends payable, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,553
|
|
|
|
|
|
|
|
|
| Shares exercised |
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
| Gain (Loss) on Sale of Assets and Asset Impairment Charges |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,198,438
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
$ 146,624
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
398,675
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants |
|
|
|
$ 2,031,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,951,356
|
$ 2,031,249
|
|
|
|
|
|
|
|
| Stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,750
|
|
|
|
|
|
|
|
|
| Preferred stock value share |
|
|
0.00001
|
|
|
|
|
|
|
|
|
|
|
$ 0.00001
|
|
|
|
|
$ 0.00001
|
|
|
$ 0.00001
|
$ 0.00001
|
|
$ 0.00001
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
$ 32.00
|
$ 32.00
|
|
|
$ 40.00
|
|
|
$ 32.50
|
|
|
|
|
|
|
|
|
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
| Deemed dividend |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 439,427
|
|
|
|
|
|
|
|
|
| Share price |
|
|
16.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 16.00
|
|
$ 1.00
|
$ 1.00
|
|
$ 18.80
|
|
|
|
| Deemed contribution |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 31,423
|
|
|
|
|
|
|
|
|
| Stock issued for conversion, vallue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The
Series A Preferred Stock sold in the Company’s 2018 and 2019 private placement offerings included warrants to be issued upon
the earlier of a closing of the sale of shares of common stock to the public or upon a listing of the Company’s common stock.
The warrants will be exercisable for a period of three years after the date of issuance at an exercise price contingent on the terms
of the public offering. The initial form of the warrants were expected to include contingent call features based on the terms of the
public offering. As originally drafted, if an initial public offering occurs at a price at or above $111.04, then the warrants are
callable if the 20-day VWAP of the common stock in at or above 150% of the variable exercise price. In the scenario where the common
stock is listed with a common stock issuance price below $111.04, then the warrants are callable if the 20-day VWAP of the common
stock is at or above the $166.56 exercise price. Upon the issuance of the warrants in September 2022, the contingent call features
were not included in the agreements. Given the variability in the number of warrants and exercise price, the detachable warrants
contained terms and features that gave rise to liability classification.
|
|
|
|
|
|
|
|
|
| Warrant share price |
|
|
$ 166.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 166.56
|
|
|
|
|
|
|
|
|
| Additional paid in capital |
|
|
$ 26,518,433
|
|
|
|
|
|
|
|
|
|
|
$ 31,664,226
|
|
|
29,402,533
|
[1] |
$ 31,664,226
|
29,402,533
|
[1] |
$ 29,489,055
|
$ 26,518,433
|
$ 12,063,940
|
|
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
|
|
10.00%
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00%
|
|
| Warrant term |
|
|
|
|
|
|
|
|
|
|
|
4 years 6 months
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Volatility rate |
|
|
86.10%
|
|
80.00%
|
83.60%
|
|
|
86.30%
|
|
|
82.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
2.66%
|
2.55%
|
|
|
1.27%
|
|
|
3.43%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Four year warrant to purchase |
|
|
|
|
|
62,500
|
|
|
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate intrinsic value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cumulative dividends percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.50%
|
|
|
|
|
|
|
|
|
| Preferred stock value share |
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000
|
|
|
|
|
|
|
|
|
| Additional paid in capital |
|
|
$ 756,723
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 756,723
|
|
|
|
|
|
|
|
|
| Warrants liability |
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
|
|
| Warrants obligation liability |
|
|
$ 421,768
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 421,768
|
|
|
|
|
|
|
|
|
| Boustead Securities LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Debt, principal |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,172,850
|
|
|
|
|
$ 1,408,050
|
|
|
$ 1,925,700
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
22,535
|
|
|
|
|
|
|
|
|
|
|
8,909
|
|
|
|
|
8,909
|
|
|
8,909
|
22,535
|
|
|
|
|
|
|
|
|
| Exercise price per share |
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
$ 97.52
|
|
$ 18.80
|
|
|
|
|
$ 18.80
|
|
|
$ 18.80
|
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 99,543
|
|
|
$ 99,543
|
|
|
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
32.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share price |
|
|
|
|
$ 20.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest rate |
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.00%
|
|
|
|
|
|
|
|
|
| Volatility rate |
|
|
|
|
80.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
2.66%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Issuance of warrants shares |
|
|
|
|
625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
$ 40.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.96%
|
|
|
|
|
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
|
|
|
|
|
|
|
|
$ 99.92
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.81%
|
|
|
|
|
|
|
|
|
| IPO [Member] | Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cumulative dividends, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,213
|
|
|
|
|
|
|
|
|
| Cumulative dividends percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8.50%
|
|
|
|
|
|
|
|
|
| Conversion price percentage |
|
|
90
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
90
|
|
|
|
|
|
|
|
|
| Share price |
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
| conversion price |
|
|
$ 28.80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 28.80
|
|
|
|
|
|
|
|
|
| Cumulative dividends |
|
|
$ 71,009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 71,009
|
|
|
|
|
|
|
|
|
| Stock issued for conversion, vallue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 402,064
|
|
|
|
|
|
|
|
|
| IPO [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,113
|
|
|
|
|
|
|
|
|
| Alliance Global Partners [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Retainer fee |
$ 50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alliance Global Partners [Member] | Offering [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price |
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Right offering |
|
4,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Escrow deposit |
|
$ 2,250,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Initial public offering description |
|
Unless the parties waive
the conditions to closing, in the event the full $4,500,000 is not raised, whether through SRO LLC or through the Company’s existing
stockholders, the Company will not close on the offering and any funds raised and held in escrow will be returned to investors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Commitment fee |
|
$ 112,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Related expense |
|
$ 40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
400,000
|
|
100,000
|
700,000
|
|
66,960
|
$ 131,965
|
|
|
|
|
|
|
|
|
| Compensation under research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
13,033
|
|
|
0
|
|
60,019
|
41,190
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
45,275
|
|
|
$ 37,583
|
|
227,886
|
$ 95,438
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized compensation cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 145,504
|
|
|
|
|
$ 145,504
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 1 month 20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized compensation cost |
|
|
$ 61,111
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 231,550
|
$ 61,111
|
|
|
|
|
|
|
|
|
| Weighted Average Life (Years), Outstanding Ending |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year 21 days
|
1 year 9 months 29 days
|
|
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] | Directors And Officers [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
12,500
|
|
53,455
|
19,916
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
$ 196,000
|
|
$ 141,840
|
$ 291,400
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted Stock Units (RSUs) [Member] | Directors Officers and Consultants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32,415
|
4,449
|
|
|
|
|
|
|
|
|
| Restricted stock award granted value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 352,400
|
$ 100,000
|
|
|
|
|
|
|
|
|
| Restricted Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for conversion of convertible debt, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,650
|
|
|
|
|
|
|
|
|
|
| 2018 Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock reserved for future issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,000,000
|
|
|
|
|
|
|
|
|
3,000,000
|
| Share granted under equity incentive plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
125,734
|
|
|
|
|
125,734
|
|
|
84,779
|
|
|
|
|
|
|
|
|
|
| Number of shares vested under plan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84,396
|
|
|
|
|
|
|
|
|
|
|
|
|
| Alto Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,909
|
|
|
|
|
| Exercise price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 18.80
|
|
|
|
|
| Bridge Financing [Member] | Alliance Global Partners [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price |
$ 1,350,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 Convertible Note Derivative [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,438
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,475
|
|
|
|
|
|
|
|
|
| December 2021 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
66,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66,250
|
|
|
|
|
|
|
|
|
| August 2022 Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 121,875
|
|
|
|
|
|
|
|
|
| 2022 Convertible Bridge Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price per share |
|
|
$ 0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.08
|
|
|
|
|
|
|
|
|
| Commitment fee |
|
|
|
|
|
|
$ 64,285
|
$ 64,285
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| conversion price |
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
6.00%
|
6.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 Convertible Bridge Notes [Member] | Boustead Securities LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
2,582
|
|
|
|
|
|
|
|
|
2,582
|
|
|
|
|
|
|
|
|
|
|
2,582
|
|
|
|
|
|
|
|
|
| Exercise price per share |
|
|
$ 16.00
|
|
|
|
|
|
|
|
|
$ 16.00
|
|
|
|
|
|
|
|
|
|
|
$ 16.00
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 92,336
|
|
|
|
|
|
|
|
|
| Interest rate |
|
|
|
|
|
|
10.00%
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for conversion of convertible debt, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
719,148
|
|
|
62,761
|
|
797,345
|
297,625
|
|
|
36,876
|
|
|
|
|
|
|
|
|
| Debt, principal |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,172,850
|
|
|
$ 331,800
|
|
$ 1,408,050
|
$ 1,925,700
|
|
$ 1,925,700
|
|
|
|
|
|
|
|
|
|
| Accrued interest settled with common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
35,888
|
|
|
54,096
|
|
54,670
|
294,927
|
|
294,927
|
|
|
|
|
|
|
|
|
|
| Loss on settlement of convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 762,186
|
|
|
$ 43,414
|
|
$ 833,501
|
$ 477,221
|
|
$ 477,221
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
5,002
|
3,722
|
15,625
|
1,876
|
|
24,349
|
1,876
|
|
10,650
|
3,500
|
|
|
|
|
|
|
|
|
| Shares issued for round up of reverse split fractional shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
115,716
|
|
|
|
|
115,716
|
|
|
|
|
|
|
|
|
|
|
|
|
| Restricted stock award granted value |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for dividends payable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 402,064
|
|
|
|
|
|
|
|
|
| Cumulative dividends, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
105
|
|
|
|
|
|
|
|
|
| Conversion of Stock, Shares Issued |
|
|
|
|
|
|
|
|
|
5,625,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock issued for cash upon initial public offering and exercise of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4
|
|
|
|
|
|
|
|
|
| Stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
297,625
|
352,443
|
|
|
|
|
|
|
|
|
| Share price |
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 32.00
|
|
|
|
|
|
|
|
|
| Stock issued for conversion, vallue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | IPO [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
42,113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,113
|
|
|
|
|
|
|
|
|
| Stock issued upon completion |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,951,356
|
|
|
|
|
|
|
|
|
| Cumulative dividends, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,553
|
|
|
|
|
|
|
|
|
| Four year warrant to purchase |
|
|
|
|
|
|
|
|
|
|
|
21,453
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Over-Allotment Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price per share |
|
|
|
|
|
|
|
|
|
|
|
$ 97.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
$ 111,296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
|
|
|
|
|
|
|
$ 50.88
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant term |
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Volatility rate |
|
|
|
|
|
|
|
|
|
|
|
101.40%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
|
|
|
|
|
|
|
3.74%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Four year warrant to purchase |
|
|
|
|
|
|
|
|
|
|
|
3,218
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Black Scholes Model [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price per share |
|
|
|
|
|
|
|
|
|
|
|
$ 97.52
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value adjustment of warrants |
|
|
|
|
|
|
|
|
|
|
|
$ 426,752
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price |
|
|
|
|
|
|
|
|
|
|
|
$ 32.50
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant term |
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Volatility rate |
|
|
|
|
|
|
|
|
|
|
|
101.80%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Risk free rate |
|
|
|
|
|
|
|
|
|
|
|
3.27%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | 2022 Convertible Note Derivative [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cumulative dividends, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36,876
|
|
|
|
|
|
|
|
|
| Conversion of Stock, Shares Issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,438
|
|
|
|
|
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
127,260
|
|
|
|
|
| Exercise price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 18.80
|
|
|
|
|
| Common stock issued for cash, shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
352,443
|
|
|
|
|
|
|
|
|
| Warrant [Member] | Alto Convertible Note [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants to purchase |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,909
|
|
|
|
|
| Exercise price per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 18.80
|
|
|
|
|
| Warrant Liability Boustead Placement Agent Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant liabilities exercised |
|
|
|
|
|
|
|
|
|
|
|
$ 64,140
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|